Frost & Sullivan Independent Equity Research
RedHill Biopharma Ltd.: RedHill gives up migraine product (RHB-103). Upside remains, but the price target is decreased to NIS 2.27.
![redhill redhill](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/redhill-nx7oeooppwzdf81hcfxh8nobo63au3cco6m1rxg31y.png)
Company: RedHill Biopharma
Sector: Pharmaceuticals
Report type: Update Report
Published on: December 13, 2017